

CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office : - Empire House, 3rd Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001

• Tel.No. (022) 22078381, 22078382 • Fax No.: (022) 22074294 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

Date: 18th July, 2017

To,
Bombay Stock Exchange Ltd.
Department of Corporate Services
25th Floor, P.J.Towers, Dalal Street,
Mumbai-400 001

Script ID : 506365

Subject : SUBMISSION OF COMPLIANCES UNDER SECURITIES AND EXCHANGE BOARD OF INDIA (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015

Dear Sirs,

We are enclosing herewith Quarterly Compliances pursuant to Securities And Exchange Board of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 for Quarter ended 30th June, 2017 as under -


1.	Regulation 33	Un-audited Quarterly Financial Results, for the Quarter ended 30/06/2017 along with Limited Review Report issued by our Auditors, M/s. VMD & Co., Chartered Accountant, Mumbai
2.		Outcome of the Board Meeting Held on 18/07/2017

You are requested to take this on your records.

Thanking You.

Yours Faithfully,

FOR CHEMO PHARMA LABORATORIES LIMITED



ASHOK SOMANI
DIRECTOR
(DIN NO. - 03063364)



CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office :- Empire House, 3rd Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001

• Tel.No. (022) 22078381, 22078382 • Fax No.: (022) 22074294 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2017

Sr. No.	Particulars	STANDLONE			
		Quarter Ended		Year Ended	
		30th June, 2017	31st March, 2017	30th June, 2016	31st March 2017
		Unaudited	Audited	Unaudited	Audited
1	Income from Operations				
	a. Net Sales/ Income from Operation (Net of Excise Duty)	-	-	-	-
	b. Other Operating Income	1,377	53,114	924	56,080
	Total Income from Operations (Net)	1,377	53,114	924	56,080
2	Expenses				
	a. Cost Materials consumed	-	-	-	-
	b. Purchase of Stock-in-Trade	-	-	-	-
	c. Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	-	-	-	-
	d. Employee Benefits Expenses	244	234	191	805
	e. Depreciation and Amortisation Expenses	-	-	-	-
	f. Other Expenses (Any Item exceeding 10% of the Total Expenses relating to continuing Operations to be shown seperately)	165	471	36	872
	i) Professional Charges	67	409	20	699
	ii) Share Registry Expenses	15	26	14	92
	iii) Annual Listing Fees	298	-	256	256
	g. Finance Costs	-	-	-	-
	Total Expenses	789	1,140	517	2,724
3	Profit/(Loss) from Operation before Other Income, Finance Costs and Exceptional Items	588	51,975	407	53,356
4	Exceptional Items	-	-	-	-
5	Net Profit/(Loss) Extra ordinary before Tax	588	51,975	407	53,356
6	Extra Ordinary Items	-	-	-	-
7	Net Profit/(Loss) before Tax	588	51,975	407	53,356
8	Tax Expenses (A.Y. 2017-18)	5,177	6,515	-	6,515
9	Net Profit/(Loss) after Taxes	(4,589)	45,460	407	46,841
10	Paid-up Capital Equity Share (Face Value of Rs.10/- each)	15,000	15,000	15,000	15,000
11	Reserves excluding Revaluation Reserve as per Balance Sheet of Previous Accounting Year	85,226	85,226	38,385	85,226
12	Earnings per Share (before Extra Ordinary Items) (of Rs.____/- each) (not Annualised):				
	a. Basic	(3.06)	30.31	0.27	31.23
	b. Diluted				
13	Earnings per Share (after Extra Ordinary Items) (of Rs.____/- each) (not Annualised):				
	a. Basic	(3.06)	30.31	0.27	31.23
	b. Diluted				

Notes :

- The above Unaudited Financial Results for the Quarter Ended 30.06.2017 have been reviewed by the Audit Committee in their Meeting held on 18.07.2017 and approved by the Board of Directors of its Meeting held on 18.07.2017. The Limited Review Report of Auditors M/s VMD & Co. was also taken on record by the Board in its Meeting.
- The Company is not having any Subsidiary Company and having one segment.

Place : Mumbai
Date : 18th July, 2017



For Chemo - Pharma Laboratories Limited

Ashok Somani

Ashok Somani
Director



LIMITED REVIEW REPORT

We have reviewed the accompanying Statement of unaudited financial results of **M/S CHEMO PHARMA LABORATORIES LTD.**, Mumbai for the quarter ended **30th June, 2017**. This Statement is the responsibility of the Company's management and has been approved by the Board of Directors / committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagement to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our notice that causes us to believe that the accompanying Statement of unaudited financial results prepared in accordance with applicable Accounting Standards and other recognized accounting practices and polices has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

NO: C/05/0717
Dated: 18/07/2017
Place: MUMBAI



For M/s VMD & CO.
Chartered Accountants.
FRN: 12502W


CA AMIT GANPULE
PARTNER
MRN: 114222